These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000623-16 A retrospective study to compare the 3-year antiviral efficacy of nevirapine and efavirenz in combination with D4T and 3TC in 2NN patients 2005-12-15 due-trials
Reported results 2004-001100-12 A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week tre... 2005-03-18 due-trials
Reported results 2004-001317-34 A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule... 2006-06-09 due-trials
Reported results 2004-001988-21 A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap... 2006-08-17 due-trials
Reported results 2004-002143-27 A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL)... 2005-12-17 due-trials
Reported results 2004-002166-38 A 12-week randomised, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18µg q.d. in patients with CIOD and a concomitant diagnosis of ast... 2006-10-27 due-trials
Reported results 2004-002241-12 Ensayo clínico de fase IIIb - IV, aleatorizado y abierto, para evaluar la eficacia y seguridad de tenecteplasa junto con heparina no fraccionada administrada previo a la realización de PCI primaria, e... 2006-04-22 due-trials
Reported results 2004-003742-18 A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study) 2006-05-02 due-trials
Reported results 2004-003986-34 A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normot... 2005-10-14 due-trials
Reported results 2004-004590-28 Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placeb... 2005-06-30 due-trials
Reported results 2004-005238-37 A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (25 µg salmeterol), administered a... 2006-02-16 due-trials
Reported results 2005-000175-17 A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function. 2006-06-01 due-trials
Reported results 2005-000317-35 A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-smal... 2007-01-02 due-trials
Completed, but no date, and reported results 2005-000650-79 A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Pa... bad-data
Reported results 2005-000841-12 A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inhaler... 2005-12-07 due-trials
Reported results 2005-000918-13 A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (12.5 µg, 25 µg and 50 µg salmeter... 2006-02-07 due-trials
Reported results 2005-001021-28 .A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 w... 2007-01-11 due-trials
Reported results 2005-001372-12 An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune ta... 2007-11-23 due-trials
Reported results 2005-001866-15 A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (... 2008-09-26 due-trials
Reported results 2005-001998-10 A phase III, randomized, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens (75mg day 1 followed by 150 mg day 2-completion, an... 2006-06-26 due-trials
Reported results 2005-001999-12 'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s... 2009-07-21 due-trials
Reported results 2005-002427-14 A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer 2008-11-12 due-trials
Reported results 2005-002442-19 A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ... 2006-08-03 due-trials
Reported results 2005-002536-94 'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0... 2011-08-19 due-trials
Reported results 2005-002851-41 Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ... 2007-08-10 due-trials
Reported results 2005-003000-11 An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o... 2007-01-30 due-trials
Reported results 2005-003176-38 A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours 30 minutes after stroke onset 2008-02-11 due-trials
Reported results 2005-003771-20 A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffer... 2006-10-18 due-trials
Reported results 2005-003788-22 A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable... 2008-07-11 due-trials
Reported results 2005-003894-26 Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie... 2009-04-01 due-trials
Reported results 2005-004005-28 An open, randomised clinical Phase II trial to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536 in comparison to 50 mg of i.v. BI 2536 administered on d... 2008-03-25 due-trials
Reported results 2005-004321-26 A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nevira... 2008-09-18 due-trials
Reported results 2005-004330-40 - Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ... 2011-02-08 due-trials
Reported results 2005-004597-24 A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally o... 2007-08-21 due-trials
Reported results 2005-004698-39 Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily) i... 2007-09-12 due-trials
Reported results 2005-004949-34 A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with ne... 2009-04-22 due-trials
Reported results 2005-005023-33 Ensayo para evaluar la seguridad y eficacia de Tipranavir (TPV) potenciado con dosis bajas de ritonavir (TPV/r) 500 mg/200 mg dos veces al día en pacientes VIH-positivos co-infectados con VCH o VBH,... 2008-10-08 due-trials
Reported results 2005-005225-54 A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole Sifrol, Mirapexin 0.125-0.75 mg/day per os for 12 weeks to investigate the effects on RLS symptoms IRL... 2007-07-04 due-trials
Reported results 2005-005249-21 A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer 2008-12-19 due-trials
Reported results 2005-005253-22 An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-wee... 2008-11-24 due-trials
Reported results 2005-005255-18 A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic ho... 2008-02-14 due-trials
Reported results 2005-005264-86 Ensayo para evaluar la seguridad, eficacia y farmacocinética de TipRanavir potenciado con dosis bajas de ritonavir (TPV/r) 500 mg/200 mg dos veces al día en una población VIH-positiva con diversidad ... 2008-10-20 due-trials
Reported results 2005-005368-10 A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi... 2008-06-09 due-trials
Reported results 2005-005615-21 A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Tiotr... 2008-02-20 due-trials
Reported results 2005-005616-25 A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de... 2008-10-13 due-trials
Reported results 2005-005985-35 A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 an... 2007-02-09 due-trials
Reported results 2005-006128-13 A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p... 2007-06-23 due-trials
Exempt, with results 2006-000613-38 An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in... 2009-10-27 not-yet-due
Reported results 2006-000822-30 A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aerosol C... 2007-11-19 due-trials
Reported results 2006-001009-27 A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th... 2009-02-06 due-trials
Reported results 2006-001618-34 An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression 2008-08-26 due-trials
Reported results 2006-001975-40 A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epit... 2008-07-09 due-trials
Reported results 2006-002018-36 An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no... 2009-06-16 due-trials
Reported results 2006-002311-27 A randomized, double-blind, placebo-controlled, five parallel group study investigating the efficacy and safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks i... 2007-09-28 due-trials
Reported results 2006-002694-52 A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety an... 2008-04-04 due-trials
Reported results 2006-002814-37 A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole 2010-01-04 due-trials
Reported results 2006-002875-42 A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci... 2011-04-01 due-trials
Reported results 2006-003048-52 A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde... 2009-02-15 due-trials
Ongoing 2006-003385-34 The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma. not-yet-due
Reported results 2006-004086-33 Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat... 2009-05-26 due-trials
Reported results 2006-004423-11 An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-... 2009-06-12 due-trials
Reported results 2006-004528-35 A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992... 2007-06-18 due-trials
Reported results 2006-004529-27 Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC... 2009-02-09 due-trials
Reported results 2006-004610-41 A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial) 2010-06-30 due-trials
Reported results 2006-004828-36 Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivere... 2008-01-14 due-trials
Reported results 2006-004829-29 Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µ... 2008-10-03 due-trials
Reported results 2006-004870-28 Prospective, randomized, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of st... 2009-02-05 due-trials
Reported results 2006-005256-33 A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-s... 2008-05-16 due-trials
Reported results 2006-006276-38 A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P... 2010-07-02 due-trials
Reported results 2006-006431-42 A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi... 2008-08-28 due-trials
Reported results 2007-000032-68 A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv... 2009-03-20 due-trials
Reported results 2007-000073-39 A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm... 2008-11-25 due-trials
Reported results 2007-000074-23 A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm... 2008-12-18 due-trials
Reported results 2007-000207-15 A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalati... 2009-06-30 due-trials
Reported results 2007-001219-44 Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2... 2012-09-07 due-trials
Reported results 2007-001840-33 Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, on... 2010-04-01 due-trials
Reported results 2007-001946-42 A multinational, randomised, double-blind, placebo. and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50µg, 100µg, 200µg) of BEA 2180 to tiotropium 5 µ... 2009-05-05 due-trials
Reported results 2007-001991-34 A randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with bisacodyl (Dulcolax®) tablets 10 mg administered orally, once daily, in... 2009-06-02 due-trials
Reported results 2007-002087-10 A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administered o... 2009-01-07 due-trials
Reported results 2007-002409-36 An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5... 2008-10-14 due-trials
Reported results 2007-002410-19 An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table... 2009-04-09 due-trials
Reported results 2007-002421-68 An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi... 2009-02-09 due-trials
Reported results 2007-002422-29 An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ... 2009-09-16 due-trials
Reported results 2007-002448-10 A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks w... 2009-06-17 due-trials
Reported results 2007-002450-28 A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient gly... 2009-05-21 due-trials
Reported results 2007-002456-41 A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d... 2010-01-22 due-trials
Reported results 2007-002457-24 A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly... 2009-07-16 due-trials
Reported results 2007-002522-29 A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona... 2013-07-03 due-trials
Reported results 2007-002586-12 Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm... 2011-12-31 due-trials
Reported results 2007-002630-11 A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220... 2009-11-16 due-trials
Reported results 2007-002631-86 A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto... 2011-05-05 due-trials
Reported results 2007-003169-42 A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M... 2008-09-30 due-trials
Reported results 2007-003353-90 A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipe... 2008-05-22 due-trials
Reported results 2007-003654-29 A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne... 2011-11-24 due-trials
Reported results 2007-003742-15 A randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of four weeks treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation po... 2008-09-16 due-trials
Reported results 2007-004076-38 A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder 2009-11-06 due-trials
Reported results 2007-004234-16 Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD). 2010-07-23 due-trials
Reported results 2007-004235-37 Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD). 2010-08-02 due-trials
Reported results 2007-004301-99 Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc... 2009-10-28 due-trials
Reported results 2007-004328-18 A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi... 2008-06-09 due-trials
Reported results 2007-004585-40 A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea... 2010-12-21 due-trials
Reported results 2007-004803-36 Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in p... 2017-11-13 due-trials
Reported results 2007-004805-80 Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy 2009-08-28 due-trials
Reported results 2007-005087-26 Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg Tio... 2009-02-10 due-trials
Reported results 2007-005107-17 A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter... 2008-11-21 due-trials
Reported results 2007-005134-36 A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala... 2008-11-21 due-trials
Reported results 2007-005135-28 A randomised, double–blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/ 25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Tiotr... 2009-08-26 due-trials
Exempt, with results 2007-005684-10 An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myelo... 2010-03-30 not-yet-due
Reported results 2007-005983-28 Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ... 2013-10-05 due-trials
Reported results 2007-007536-25 Randomized, Open-label study of Dabigatran Etexilate, a Novel, oral, Direct Thrombin-inhibitor in clinical development, in Elective Percutaneous Coronary Intervention. (D-Fine) 2010-08-07 due-trials
Reported results 2007-007865-19 A 4-week, randomized, double blind, double dummy, placebo controlled, parallel group study comparing the influence of BI 1356 (5 mg) and sitagliptin (100 mg) administered orally once daily on various ... 2008-11-19 due-trials
Reported results 2008-000079-31 A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ... 2009-07-06 due-trials
Trial is partly outside EEC, and reported results 2008-000342-32 An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Tourette ... 2009-08-14 bad-data
Reported results 2008-000343-33 A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate... 2009-08-07 due-trials
Reported results 2008-000562-23 Randomised, Double-Blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination (FDC) with 5μg T... 2009-02-20 due-trials
Reported results 2008-000640-14 A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m... 2009-10-06 due-trials
Reported results 2008-000641-54 A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p... 2009-10-31 due-trials
Reported results 2008-000750-13 A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients. 2011-02-11 due-trials
Reported results 2008-000873-40 Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia... 2009-12-11 due-trials
Reported results 2008-000874-19 A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov... 2010-06-30 due-trials
Reported results 2008-001156-43 A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail... 2010-04-02 due-trials
Reported results 2008-001264-37 A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients 2013-07-04 due-trials
Reported results 2008-001413-14 A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee... 2011-07-25 due-trials
Reported results 2008-001414-25 A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week... 2011-07-25 due-trials
Reported results 2008-001546-67 A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients 2012-06-19 due-trials
Reported results 2008-001640-40 A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500... 2010-06-25 due-trials
Reported results 2008-001933-84 A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation... 2010-12-02 due-trials
Reported results 2008-001934-28 A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation... 2010-12-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-002072-10 Multicenter, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in... 2015-12-30 bad-data
Reported results 2008-002731-32 A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropatic ... 2010-06-23 due-trials
Reported results 2008-003118-86 A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient gly... 2010-01-14 due-trials
Reported results 2008-003538-11 Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl... 2011-11-28 due-trials
Exempt, with results 2008-003617-27 An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in pat... 2021-04-23 not-yet-due
Reported results 2008-003647-36 Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1... 2010-09-21 due-trials
Reported results 2008-003704-67 Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1... 2010-09-27 due-trials
Reported results 2008-003932-40 A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients sufferi... 2009-11-17 due-trials
Trial is partly outside EEC, and reported results 2008-004460-39 A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-... 2009-06-23 bad-data
Reported results 2008-004681-55 An open label, phase IIIb, randomized parallel group study to assess the efficacy and safety of switching HIV-1 infected patients successfully treated with a Nevirapine IR based regimen to Nevirapine ... 2012-01-10 due-trials
Reported results 2008-005248-17 RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge... 2013-03-04 due-trials
Exempt, with results 2008-005364-14 A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients. 2013-07-18 not-yet-due
Reported results 2008-005615-18 LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa... 2017-03-16 due-trials
Trial is partly outside EEC, and reported results 2008-005855-61 An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension pha... 2012-09-10 bad-data
Reported results 2008-006288-36 Phase II open label trial to assess the efficacy and the impact on QTcF of continuous oral BIBW 2992 at a daily dose of 50 mg in patients with relapsed or refractory solid tumours including patients w... 2011-04-27 due-trials
Reported results 2008-006334-10 Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations ... 2009-07-20 due-trials
Reported results 2008-006625-14 Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily... 2011-12-19 due-trials
Reported results 2008-006831-10 Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c... 2016-09-26 due-trials
Trial is outside EEC, and reported results 2008-006866-27 Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years bad-data
Reported results 2008-007097-38 A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-contai... 2013-07-26 due-trials
Reported results 2008-007711-32 A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25)... 2010-04-23 due-trials
Reported results 2008-007938-21 A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients 2011-06-16 due-trials
Reported results 2008-008127-15 A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog... 2013-02-11 due-trials
Reported results 2008-008296-33 A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie... 2011-10-20 due-trials
Reported results 2008-008494-59 A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m... 2011-06-16 due-trials
Reported results 2009-009516-44 A randomised, open label, parallel group Phase II study comparing the efficacy and tolerability of BIBF 1120 versus sunitinib in previously untreated patients with Renal Cell Cancer. 2020-06-19 due-trials
Reported results 2009-010668-40 A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram... 2013-12-26 due-trials
Reported results 2009-010669-22 A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ... 2013-12-09 due-trials
Exempt, with results 2009-011925-14 A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. 2016-10-12 not-yet-due
Reported results 2009-011996-59 An open label, partially randomised Phase II trial to investigate the efficacy and safety of BIBW 2992 in patients with metastatic colorectal cancer who never received prior anti-EGFR treatment 2012-03-29 due-trials
Reported results 2009-012579-90 Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and ri... 2011-04-11 due-trials
Reported results 2009-013157-15 A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... 2018-08-21 due-trials
Reported results 2009-013269-24 Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ora... 2010-04-22 due-trials
Reported results 2009-013289-20 A Phase III, randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with ins... 2012-05-14 due-trials
Reported results 2009-013395-48 A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation ... 2011-02-17 due-trials
Reported results 2009-013549-27 A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ... 2010-09-28 due-trials
Trial is partly outside EEC, and reported results 2009-013618-29 Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y... 2016-02-18 bad-data
Reported results 2009-013668-38 A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati... 2012-05-09 due-trials
Reported results 2009-013788-21 A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis 2016-09-26 due-trials
Reported results 2009-014395-21 Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of... 2011-04-27 due-trials
Reported results 2009-014416-35 Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of... 2011-04-05 due-trials
Reported results 2009-014417-27 Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat... 2011-01-04 due-trials
Reported results 2009-014418-86 Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat... 2011-01-10 due-trials
Reported results 2009-014551-80 Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ... 2011-08-09 due-trials
Reported results 2009-014563-39 Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29... 2016-01-07 due-trials
Reported results 2009-014880-38 A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® Inh... 2011-02-03 due-trials
Reported results 2009-015255-25 A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age... 2011-07-21 due-trials
Reported results 2009-015476-98 LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio... 2018-07-26 due-trials
Reported results 2009-015713-51 A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut... 2013-06-22 due-trials
Reported results 2009-015770-35 Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox... 2014-06-04 due-trials
Exempt, with results 2009-015911-42 A phase Ib open label clinical trial of continuous once daily oral treatment using BIBW 2992 plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with progression following prior erlo... not-yet-due
Reported results 2009-016154-40 A randomised, double-blind, placebo-controlled parallel group efficacy and safety trial of BI 10773 (10 and 25 mg administered orally once daily) over 24 weeks in patients with type 2 diabetes mellitu... 2012-05-24 due-trials
Reported results 2009-016178-33 A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ... 2015-09-22 due-trials
Reported results 2009-016179-31 A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap... 2012-08-28 due-trials
Reported results 2009-016243-20 A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 10773 and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 diab... 2012-03-19 due-trials
Reported results 2009-016244-39 A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per... 2015-08-28 due-trials
Reported results 2009-016251-21 A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv... 2011-11-16 due-trials
Reported results 2009-016258-41 A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia... 2012-02-03 due-trials
Reported results 2009-016971-31 A phase III, randomised, double-blind, placebo-controlled parallel group safety and efficacy study of linagliptin (5 mg administered orally once daily) over 12 weeks followed by a 40 week double-blind... 2012-07-18 due-trials
Trial is partly outside EEC, and reported results 2009-017004-91 A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 ... 2016-02-11 bad-data
Reported results 2009-017336-40 Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched 2011-07-07 due-trials
Ongoing 2009-017661-34 An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat... not-yet-due
Reported results 2009-017745-55 A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg, 2.... 2011-05-23 due-trials
Reported results 2009-018004-18 A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dail... 2012-11-13 due-trials
Reported results 2009-018005-43 A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dai... 2012-11-07 due-trials
Reported results 2009-018006-21 A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twic... 2011-08-19 due-trials
Reported results 2009-018197-66 Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par... 2014-10-30 due-trials
Reported results 2010-018471-26 A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 μ... 2012-01-09 due-trials
Reported results 2010-018708-99 An open-label, phase II study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagl... 2013-07-08 due-trials
Reported results 2010-018723-26 An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patients... 2013-05-22 due-trials
Reported results 2010-019707-32 LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology. 2017-06-19 due-trials
Reported results 2010-019802-17 A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ... 2012-03-07 due-trials
Reported results 2010-019968-37 A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2... 2013-04-22 due-trials
Trial is partly outside EEC, and reported results 2010-021093-11 A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive... 2013-12-27 bad-data
Reported results 2010-021375-92 A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp... 2014-12-01 due-trials
Reported results 2010-021415-16 Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase... 2014-08-26 due-trials
Reported results 2010-021715-17 A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype... 2014-05-15 due-trials
Reported results 2010-021716-42 A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib... 2014-03-12 due-trials
Reported results 2010-021734-59 Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV... 2014-06-19 due-trials
Trial is partly outside EEC, and reported results 2010-021778-13 A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms... 2013-11-12 bad-data
Reported results 2010-021945-29 LUX-Breast 2;An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant trea... 2017-03-13 due-trials
Reported results 2010-022458-18 A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg, 2... 2012-10-29 due-trials
Reported results 2010-022685-27 A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt 2013-06-03 due-trials
Reported results 2010-022718-17 A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc... 2013-05-23 due-trials
Reported results 2010-023112-14 A Phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 µg and 5 µg once... 2012-04-19 due-trials
Ongoing, reported early 2010-023167-17 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 22.7, 45.5, and 90.9 µg b.... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-023168-41 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 45.5, 90.9 and 181.8 μg b.... 2011-12-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023169-23 A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg b.i... 2011-11-11 bad-data
Completed, but no date, and reported results Terminated 2010-023326-20 A randomized, double blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d... bad-data
Reported results 2010-023499-25 A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea... 2011-09-30 due-trials
Reported results 2010-024251-87 A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo... 2013-10-09 due-trials
Reported results 2010-024252-29 A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib... 2013-11-18 due-trials
Reported results 2010-024454-10 An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer 2014-11-18 due-trials
Reported results 2011-000141-20 A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in... 2014-06-24 due-trials
Reported results 2011-000347-25 A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi... 2012-07-31 due-trials
Reported results 2011-000383-10 A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m... 2013-09-10 due-trials
Reported results 2011-000391-34 A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ... 2016-12-06 due-trials
Reported results 2011-000392-14 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w... 2016-09-12 due-trials
Reported results Terminated 2011-000935-98 A single dose, placebo-controlled, randomised, double-blind double dummy, 5-way crossover (7 treatments, 5 periods incomplete block), including 24-h pulmonary function tests, pharmacodynamic compariso... 2011-11-11 due-trials
Reported results 2011-001758-26 A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... 2015-12-08 due-trials
Reported results 2011-001777-43 A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... 2015-05-18 due-trials
Reported results Terminated 2011-001801-29 A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotr... 2011-11-11 due-trials
Reported results 2011-001814-33 LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung 2019-04-12 due-trials
Reported results 2011-002276-16 A randomised, double-blind, double dummy study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin bid over 14 weeks in treament nai... 2013-03-05 due-trials
Reported results 2011-002285-21 Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve 2013-06-07 due-trials
Reported results 2011-002380-24 LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b... 2017-12-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002766-21 An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez... 2021-02-01 bad-data
Trial is outside EEC, and reported results 2011-002774-23 An open-label clinical study to investigate pharmacokinetics (PK) of different doses (0.125 mg, 0.25 mg, 0.5 mg) of pramipexole administered once daily orally in pediatric patients who are individuall... bad-data
Reported results 2011-002894-48 Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, activ... 2016-10-28 due-trials
Reported results 2011-002908-33 A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated fol... 2014-09-09 due-trials
Exempt, with results 2011-003081-32 An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal Een studie naar de farmacokinetiek en effecten v... not-yet-due
Reported results 2011-003890-27 A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2 cm ointment line per applica... 2013-04-19 due-trials
Reported results 2011-004148-23 A multicenter, international, randomized, parallel group, double blind,placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE with LINAgliptin, 5 mg once daily in patients with type 2 ... 2018-01-18 due-trials
Completed, but no date, and reported results 2011-004158-24 A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatme... bad-data
Reported results 2011-004253-11 A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)... 2013-09-26 due-trials
Reported results 2011-004354-25 A 28-day randomised, placebo-controlled, double-blind parallel group phase IIa trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of 2.5 mg, 10 mg... 2014-04-20 due-trials
Reported results 2011-004659-37 A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)... 2013-11-20 due-trials
Reported results 2011-004660-30 A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)... 2013-11-26 due-trials
Reported results 2011-004710-42 Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2... 2013-08-12 due-trials
Reported results 2011-005512-28 A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af... 2014-12-04 due-trials
Reported results 2012-000095-42 A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies... 2016-09-15 due-trials
Reported results 2012-000905-53 A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we... 2013-12-03 due-trials
Reported results 2012-001873-10 A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat® inhaler, after 4 weeks of once daily [5 µg in the evening ... 2013-09-26 due-trials
Reported results 2012-002270-31 A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed dos... 2015-03-23 due-trials
Reported results 2012-002271-34 A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ... 2015-03-13 due-trials
Reported results 2012-002487-27 A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6... 2021-05-28 due-trials
Reported results 2012-002603-17 A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m... 2015-12-07 due-trials
Reported results 2012-002945-40 Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial 2016-10-18 due-trials
Reported results 2012-003533-41 A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio... 2015-03-11 due-trials
Reported results 2012-003534-17 A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b... 2014-10-21 due-trials
Reported results 2012-003535-27 A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu... 2015-03-11 due-trials
Exempt, with results 2012-004090-16 A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal... 2015-04-27 not-yet-due
Reported results 2012-004384-48 A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-con... 2015-07-31 due-trials
Reported results 2012-004544-30 A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat... 2019-01-14 due-trials
Reported results 2012-005201-48 Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex... 2018-08-28 due-trials
Reported results 2013-000808-41 Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod... 2015-03-20 due-trials
Reported results 2013-001110-15 A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer 2021-12-15 due-trials
Reported results 2013-001291-38 Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year... 2017-01-31 due-trials
Trial is partly outside EEC, and reported results 2013-002114-12 Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt... 2019-11-20 bad-data
Reported results 2013-002243-29 A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ... 2014-11-24 due-trials
Reported results 2013-002264-24 A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed do... 2015-01-13 due-trials
Trial is partly outside EEC, and reported results 2013-002304-14 An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ... 2016-02-29 bad-data
Reported results 2013-002622-23 Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial 2016-11-06 due-trials
Reported results 2013-002652-32 A randomised, placebo-controlled, double-blind, single dose, cross-over study to evaluate the efficacy and safety of orally inhaled tiotropium + olodaterol as both a fixed dose combination and a free ... 2014-06-06 due-trials
Reported results 2013-002671-18 An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d... 2015-10-31 due-trials
Reported results 2013-002902-29 A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ... 2016-11-18 due-trials
Reported results 2013-003201-26 A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl... 2017-06-05 due-trials
Reported results 2013-003444-24 Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls... 2018-10-10 due-trials
Reported results 2013-003646-16 A randomized, double-blind, placebo-controlled, parallel groups study to investigate the safety and tolerability, efficacy, pharmacokinetics and pharmacodynamics of three BI 187004 doses given once d... 2015-08-02 due-trials
Reported results 2013-003666-13 A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a... 2016-07-26 due-trials
Exempt, with results 2013-004011-41 A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following D... not-yet-due
Reported results Terminated 2013-004567-30 A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD) 2015-04-15 due-trials
Reported results 2013-004813-41 A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete... 2016-10-20 due-trials
Reported results 2013-005015-28 A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in ... 2016-06-13 due-trials
Reported results 2013-005031-24 A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... 2017-10-09 due-trials
Reported results 2013-005040-28 A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... 2017-10-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-000583-18 Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years 2019-11-19 bad-data
Reported results 2014-000904-88 A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ... 2017-04-25 due-trials
Reported results 2014-001077-14 An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbou... 2017-06-13 due-trials
Trial is partly outside EEC, and reported results 2014-001259-22 open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o... 2016-02-09 bad-data
Completed, but no date, and reported results 2014-001687-36 An open label extension trial assessing the safety and and efficay of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis. Avoin jatkotutkimus, jossa ... bad-data
Reported results 2014-001922-14 A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w... 2017-10-23 due-trials
Exempt, with results 2014-002123-10 Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,... 2020-08-05 not-yet-due
Reported results 2014-002161-30 A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small... 2018-11-16 due-trials
Reported results 2014-002275-28 A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ... 2017-03-29 due-trials
Reported results 2014-003890-40 Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial) 2016-11-14 due-trials
Reported results 2014-004544-36 A Phase III, randomized, double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with low tum... 2015-12-07 due-trials
Reported results 2014-004794-16 An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) with... 2018-05-11 due-trials
Reported results 2014-004932-20 A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week... 2018-03-19 due-trials
Reported results 2014-004959-30 A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in... 2016-10-10 due-trials
Reported results 2014-005102-38 BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with r... 2018-10-25 due-trials
Reported results 2014-005117-23 BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1) BI 65506... 2017-09-18 due-trials
Reported results 2014-005256-26 A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w... 2017-12-28 due-trials
Reported results 2015-000392-28 A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ... 2018-11-28 due-trials
Reported results 2015-000404-25 A randomized, controlled multi-centre parallel group study to assess the efficacy and safety of multiple doses of a topically applied combination containing diclofenac 2% + capsaicin 0.075% (2 g formu... 2017-07-21 due-trials
Reported results 2015-000640-42 A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit... 2017-01-31 due-trials
Exempt, with results 2015-001111-12 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit 2021-11-23 not-yet-due
Exempt, with results 2015-001477-41 A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-lin... 2016-06-20 not-yet-due
Reported results 2015-001750-15 A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active... 2020-08-18 due-trials
Reported results 2015-001834-15 An open label, single group, long term safety extension trial of BI 655066, in patients with moderately to severely active Crohn's disease 2019-06-19 due-trials
Trial is partly outside EEC, and reported results 2015-002177-37 Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate f... 2019-10-19 bad-data
Reported results 2015-002619-14 A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in pa... 2018-04-13 due-trials
Reported results 2015-002634-41 Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed tri... 2017-11-01 due-trials
Exempt, with results 2015-002892-30 An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myeloid... 2023-01-16 not-yet-due
Reported results 2015-002974-20 A randomised, double-blind, cross-over study to evaluate the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (5/5 µg) compared with tiotropium (5 µg), bo... 2017-08-14 due-trials
Reported results 2015-003148-38 A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in... 2018-06-11 due-trials
Reported results 2015-003360-37 A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) 2019-08-12 due-trials
Reported results 2015-003529-33 A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impa... 2017-10-24 due-trials
Reported results 2015-003622-13 BI 655066 (risankinumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2) Studio randomizz... 2017-09-04 due-trials
Reported results 2015-003623-65 655066/ABBV-006 (risankizumab)versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and... 2017-08-27 due-trials
Reported results 2015-003625-34 A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 / ABBV-066 / risankiumab in patients with active psoriatic arthritis 2017-08-31 due-trials
Completed, but no date, and reported results 2015-003718-25 A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated locally advanced or metastatic colorectal ca... bad-data
Reported results 2015-003879-29 A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 µg) delivered by the Respimat® inhaler versus the fr... 2017-03-13 due-trials
Reported results 2015-004412-38 RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with c... 2018-06-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-004625-14 Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg... 2016-03-28 bad-data
Reported results 2015-005079-26 ELUXA 2: An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus standard platinum doublet chemotherapy in patients with ... 2016-08-11 due-trials
Reported results 2015-005427-10 LUX-Bladder 1: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with genetic al... 2019-09-02 due-trials
Reported results 2015-005438-24 A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p... 2019-11-19 due-trials
Reported results 2016-000285-28 A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit... 2020-01-29 due-trials
Reported results 2016-000499-83 A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a... 2019-06-14 due-trials
Reported results 2016-000612-14 BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, exploratory trial comparing efficacy, endoscopic improvement, safety, and imm... 2019-05-13 due-trials
Reported results 2016-000613-79 Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparato... 2018-01-17 due-trials
Trial is partly outside EEC, and reported results 2016-000669-21 A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext... 2023-05-31 bad-data
Reported results 2016-002254-20 VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm, mu... 2019-04-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-002278-11 A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fractio... 2021-04-26 bad-data
Reported results 2016-002280-34 A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction ... 2020-05-28 due-trials
Reported results 2016-002971-91 A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ... 2020-05-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-003403-66 An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) 2023-01-25 bad-data
Reported results 2016-004572-21 Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy 2020-09-16 due-trials
Reported results 2016-004573-40 Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655... 2018-11-14 due-trials
Other 2016-004973-42 A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early interven... not-yet-due
Reported results 2016-005042-37 A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung 2020-01-13 due-trials
Reported results 2017-000100-20 Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC) 2019-10-29 due-trials
Reported results 2017-000376-28 A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with... 2020-05-28 due-trials
Exempt 2017-001221-40 Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled). 2023-11-01 not-yet-due
Completed, but no date, and reported results Terminated 2017-002369-23 A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therap... bad-data
Listed as ongoing, but also has a completion date and reported results 2017-002971-24 A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease 2024-07-11 bad-data
Reported results 2017-003090-34 Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease 2022-07-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003101-17 An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out... 2021-07-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003131-11 XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i... 2022-04-26 bad-data
Reported results 2017-004072-59 A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... 2019-10-09 due-trials
Reported results 2017-004073-14 A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... 2019-10-07 due-trials
Reported results 2017-004230-28 A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act... 2020-05-18 due-trials
Reported results 2017-004231-37 Effisayil™ 1:Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP)... 2021-01-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-000334-35 An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials 2023-05-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-000525-32 An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) 2022-08-30 bad-data
Other 2018-002344-81 An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advan... not-yet-due
Other 2018-002740-82 A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week t... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-003078-28 Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev... 2021-07-28 bad-data
Ongoing 2018-003080-56 An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP) not-yet-due
Reported results 2018-003081-14 Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ... 2022-12-20 due-trials
Reported results Terminated 2018-003487-31 Phase II long-term extension study to assess the safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis 2021-07-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-004530-14 A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted... 2022-05-24 bad-data
Reported results Terminated 2019-000261-21 A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s... 2020-04-28 due-trials
Listed as ongoing, but also has a completion date 2019-001037-13 A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in ... 2023-11-05 bad-data
Reported results 2019-001673-93 An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials 2022-09-23 due-trials
Reported results Terminated 2019-001684-77 A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis A BI 730357 vizsgálati gyógyszer... 2021-08-18 due-trials
Reported results 2019-001719-21 A randomized, double blind, placebo-controlled, multi-center, parallel group study to compare the efficacy of inhaled tiotropium + olodaterol, fixed dose combination (5μg/5μg) vs. placebo delivered by... 2020-09-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-002390-60 A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell... 2021-11-05 bad-data
Reported results 2019-002946-19 A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia... 2021-06-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-003182-17 A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis 2021-07-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-004167-45 A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. 2021-10-15 bad-data
Completed, report not yet due 2019-004264-21 A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 135... 2024-02-02 not-yet-due
Reported results 2019-004749-33 An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal 2020-11-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-000078-12 A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit... 2023-01-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2020-000189-41 An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials 2023-06-07 bad-data
Ongoing 2020-000384-23 A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for ... not-yet-due
Reported results 2020-002479-37 A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight 2022-10-07 due-trials
Completed, report not yet due 2020-002723-11 Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of ... 2023-12-21 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-002913-16 The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of dai... 2022-07-25 bad-data
Reported results 2020-002929-28 Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in pati... 2022-12-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-002930-33 Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in pati... 2023-09-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2020-003672-40 Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate or severe hidradenitis suppurativa 2022-04-27 bad-data
Ongoing 2020-003726-23 A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (C... not-yet-due
Ongoing 2020-003744-84 A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (... not-yet-due
Other 2020-003745-11 An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) not-yet-due
Listed as ongoing, but also has a completion date 2020-003760-11 A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with sch... 2024-10-01 bad-data
Listed as ongoing, but also has a completion date 2020-004527-16 A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with C... 2024-08-08 bad-data
Ongoing 2020-005554-23 A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON) not-yet-due
Listed as ongoing, but also has a completion date 2020-005587-55 An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS) 2024-04-26 bad-data
Reported results 2020-005588-29 A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati... 2021-10-04 due-trials
Reported results 2020-005770-99 Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr... 2022-05-31 due-trials
Completed, but no date, and reported results Terminated 2021-000408-39 A Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-2 i... bad-data
Listed as ongoing, but also has a completion date 2021-001285-38 Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w... 2024-06-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2021-001434-19 Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl... 2023-07-10 bad-data
Ongoing 2021-002392-20 Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma not-yet-due
Listed as ongoing, but also has a completion date 2021-003154-23 A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in pat... 2023-11-20 bad-data
Listed as ongoing, but also has a completion date 2021-003304-41 A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis 2024-05-30 bad-data
Other 2021-005171-40 Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ... not-yet-due
Ongoing 2022-001091-34 A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) not-yet-due
Ongoing 2022-001134-11 A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) not-yet-due
Other 2022-001500-18 Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenoc... not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Boehringer Ingelheim is now also responsible for the trials of: